Common Names
Geographic Range: Northeast Asia — Korea, northeastern China (Manchuria), Russian Far East. Wild populations extremely rare; primarily cultivated.
Known Contraindications
1
Compounds
3
Traditions
7
Treatments
7
Conditions
CC(C)=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C1CCC2(C)C1CCC1C3CC(OC4OC(CO)C(O)C(O)C4O)C(O)(C)C3CCC12CCYP Interaction Profile
| Enzyme | Interaction |
|---|---|
| CYP1A2 | no significant interaction |
| CYP2C9 | no significant interaction |
| CYP2D6 | weak substrate (secondary metabolites) |
| CYP3A4 | weak substrate (gut flora metabolites) |
| CYP2C19 | no significant interaction |
| clinical_note | May potentiate anticoagulants (warfarin). Possible interaction with MAOIs. CYP3A4 substrate — theoretical grapefruit interaction. INR monitoring recommended. |
| gut_flora_note | Primary metabolism via gut flora hydrolysis to compound K (ginsenoside M1). Antibiotic use may reduce ginsenoside activation. |